BRIEF-Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions

Reuters03-11

March 11 (Reuters) - Abcellera Biologics Inc :

* ABCELLERA TO COLLABORATE WITH BIOGEN TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL CONDITIONS

* ABCELLERA BIOLOGICS - WILL RECEIVE UPFRONT PAYMENT, SHOULD RESEARCH PROGRAMS ACHIEVE CERTAIN RESEARCH, DEVELOPMENTAL AND REGULATORY MILESTONES

* ABCELLERA BIOLOGICS-ELIGIBLE TO RECEIVE ADDITIONAL MILESTONE PAYMENTS SHOULD RESEARCH PROGRAMS ACHIEVE CERTAIN RESEARCH, REGULATORY MILESTONES

* ABCELLERA BIOLOGICS INC - ABCELLERA IS ALSO ELIGIBLE TO RECEIVE POTENTIAL ROYALTIES ON FUTURE NET SALES OF PRODUCTS THAT RESULT FROM COLLABORATION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2418357972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-11 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2418357972","market":"us","top_or_hot":-1,"title":"BRIEF-Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions","media":"Reuters","content":"<html><body><p>March 11 (Reuters) - Abcellera Biologics Inc   :</p><p>   * ABCELLERA TO COLLABORATE WITH BIOGEN TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL CONDITIONS</p><p>   * ABCELLERA BIOLOGICS - WILL RECEIVE UPFRONT PAYMENT, SHOULD RESEARCH PROGRAMS ACHIEVE CERTAIN RESEARCH, DEVELOPMENTAL AND REGULATORY MILESTONES</p><p>   * ABCELLERA BIOLOGICS-ELIGIBLE TO RECEIVE ADDITIONAL MILESTONE PAYMENTS SHOULD RESEARCH PROGRAMS ACHIEVE CERTAIN RESEARCH, REGULATORY MILESTONES</p><p>   * ABCELLERA BIOLOGICS INC - ABCELLERA IS ALSO ELIGIBLE TO RECEIVE POTENTIAL ROYALTIES ON <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> NET SALES OF PRODUCTS THAT RESULT FROM COLLABORATION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-11 21:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 11 (Reuters) - Abcellera Biologics Inc   :   * ABCELLERA TO COLLABORATE WITH BIOGEN TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL CONDITIONS   * ABCELLERA BIOLOGICS - WILL RECEIVE UPFRONT ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2418357972","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2418357972","pubTimestamp":1710163458,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 11 (Reuters) - Abcellera Biologics Inc   :   * ABCELLERA TO COLLABORATE WITH BIOGEN TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL CONDITIONS   * ABCELLERA BIOLOGICS - WILL RECEIVE UPFRONT ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4121":"生命科学工具和服务","BK4532":"文艺复兴科技持仓","BK4585":"ETF&股票定投概念","BK4166":"消费信贷","BK4139":"生物科技","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BIIB":"渤健公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4588":"碎股","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ABCL":"AbCellera Biologics","DFS":"发现金融","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC"},"translate_title":"简介-Abcellera与Biogen合作发现治疗神经疾病的抗体","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"DFS":1,"ABCL":0.9},"content_text":"March 11 (Reuters) - Abcellera Biologics Inc   :   * ABCELLERA TO COLLABORATE WITH BIOGEN TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL CONDITIONS   * ABCELLERA BIOLOGICS - WILL RECEIVE UPFRONT PAYMENT, SHOULD RESEARCH PROGRAMS ACHIEVE CERTAIN RESEARCH, DEVELOPMENTAL AND REGULATORY MILESTONES   * ABCELLERA BIOLOGICS-ELIGIBLE TO RECEIVE ADDITIONAL MILESTONE PAYMENTS SHOULD RESEARCH PROGRAMS ACHIEVE CERTAIN RESEARCH, REGULATORY MILESTONES   * ABCELLERA BIOLOGICS INC - ABCELLERA IS ALSO ELIGIBLE TO RECEIVE POTENTIAL ROYALTIES ON FUTURE NET SALES OF PRODUCTS THAT RESULT FROM COLLABORATIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2418357972"}